May - 2014
| Previous Next | Showing Journal 4 of 15 |
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosisthe INPULSIS Trial Investigators N Eng J Med, 2014, May 18, 2014DOI: 10.1056/NEJMoa1402584 This page is only available to Crit-IQ subscribers. To view the rest of this review and gain access to our vast array of critical care teaching tools including podcasts, vodcasts, modules, exam preparation tools, teaching aids and much more, login here, or Become a Member to register |
May |
Previous Comments
No Comments yet.
Comment
This 1 of 3 articles published in the NEJM this week reporting outcomes of new interventions for idiopathic pulmonary fibrosis (IPF). Nintedanib is an intracellular tyrosine kinase inhibitor, and previous studies have suggested it may reduce pathogenic pathways in this disease, and reduce...